(0.86%) 5 107.85 points
(0.97%) 38 595 points
(1.58%) 16 091 points
(-0.57%) $78.50
(0.74%) $2.05
(0.17%) $2 313.50
(-1.55%) $26.41
(-0.29%) $959.80
(-0.28%) $0.930
(-1.04%) $10.88
(-0.07%) $0.797
(-0.51%) $90.66
3.02% $ 56.73
@ $54.92
Wydano: 2 geg. 2024 @ 20:10
Zwrot: 3.31%
Poprzedni sygnał: geg. 1 - 22:38
Poprzedni sygnał:
Zwrot: 1.17 %
Live Chart Being Loaded With Signals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform...
Stats | |
---|---|
Dzisiejszy wolumen | 432 182 |
Średni wolumen | 1.71M |
Kapitalizacja rynkowa | 4.82B |
EPS | $0 ( 2024-02-20 ) |
Następna data zysków | ( $-1.630 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -29.24 |
ATR14 | $1.749 (3.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Kulkarni Samarth | Buy | 19 582 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 18 378 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 1 204 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 19 582 | Stock Option (Right to Buy) |
2024-03-20 | Kasinger James R. | Buy | 33 333 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
63.61 |
Last 100 transactions |
Buy: 2 415 277 | Sell: 542 570 |
Wolumen Korelacja
CRISPR Therapeutics AG Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TGTX | 0.924 |
VYNE | 0.917 |
TRKA | 0.913 |
LIXT | 0.906 |
XLRN | 0.898 |
GNLN | 0.897 |
ZGNX | 0.895 |
LITM | 0.893 |
KALV | 0.89 |
APTO | 0.886 |
10 Najbardziej negatywne korelacje | |
---|---|
CFV | -0.899 |
SITM | -0.896 |
AMRB | -0.896 |
MTSI | -0.885 |
EVBG | -0.883 |
ASRVP | -0.881 |
GMII | -0.88 |
PSCC | -0.88 |
MMAC | -0.879 |
PEBK | -0.872 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CRISPR Therapeutics AG Korelacja - Waluta/Towar
CRISPR Therapeutics AG Finanse
Annual | 2023 |
Przychody: | $370.00M |
Zysk brutto: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2023 |
Przychody: | $370.00M |
Zysk brutto: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2022 |
Przychody: | $436 000 |
Zysk brutto: | $-109.81M (-25 186.70 %) |
EPS: | $-8.36 |
FY | 2021 |
Przychody: | $914.96M |
Zysk brutto: | $914.96M (100.00 %) |
EPS: | $4.97 |
Financial Reports:
No articles found.
CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej